Endocrine Abstracts

Background: Dulaglutide has been approved as a hypoglycemic agent for the treatment of patients with T2DM. A positive effect on carbohydrate metabolism and body weight was shown in RCT.It was found that GLP-1 agonists may prevent the progression of NAFLD directly affecting lipid metabolism and inflammation.Aim: To assess the effect of dulaglutide on carbohydrate and hepatic metabolism in patients with T2DM and NAFLD in real clinica...